TETakaaki Eguchi

Takaaki Eguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takaaki Eguchi has a total of 239 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of elobixibat in combination with or switched from conventional treatments of chronic constipation: A retrospective observational study

    by Takaaki Eguchi, Osamu Inatomi, Shuhei Shintani, Kenji Momose, Tomoya Sako, Megumi Takagi, Daiki Fumihara, Kazuki Inoue, Norio Katayama, Toshiyuki Morisawa, et al.

    Background and Aim: Elobixibat is a triple mode of action laxative that increases water secretion into the colon, promotes colonic motility, and reestablishes the defecation desire. This study aims to evaluate the effectivity and safety of elobixibat in chronic constipation (CC) patients refractory to conventional laxatives.Methods: A single‐center retrospective observational study was conducted in refractory CC patients diagnosed according to the Rome IV criteria and received elobixibat between April 2018 and June 2022 at Osaka Saiseikai Nakatsu Hospital. Data were collected for spontaneous bowel movement (SBM), Bristol stool form scale (BSFS) scores, abdominal symptoms, and adverse events.Results: Eligible 311 patients were selected for the analysis. Two‐week Elobixibat treatment significantly increased SBM (times/week) from 2.9 ± 1.9 to 4.3 ± 1.9 (P < 0.0001). The BSFS score improved significantly from 3.2 ± 1.7 to 4.4 ± 1.4 (P < 0.0001). The percentages of patients with hard stool were decrease and that with normal stools were increase. Improvements in abdominal symptoms (sensation of incomplete bowel evacuation, straining, abdominal pain and distention, and difficulty defecating) were also significant (P < 0.05). These constipation symptoms were improved irrespective of patient characteristics or previous laxatives. The 43.9% of previous laxatives were discontinued at the start of or after starting elobixibat treatment. A few adverse events were observed, elobixibat was well tolerated.Conclusion: Elobixibat was effective in patients who were refractory to other laxatives, irrespective of previous therapy or patient characteristics. Elobixibat may contribute to resolving polypharmacy with single mode of action laxatives.


  • Open Access

    A novel fully covered metal stent for unresectable malignant distal biliary obstruction: results of a multicenter prospective study

    by Arata Sakai, Atsuhiro Masuda, Takaaki Eguchi, Keisuke Furumatsu, Takao Iemoto, Shiei Yoshida, Yoshihiro Okabe, Kodai Yamanaka, Ikuya Miki, Saori Kakuyama, et al.

    Background/Aims: Endoscopic self-expandable metal stent (SEMS) placement is currently the standard technique for treating unresectable malignant distal biliary obstructions (MDBO). Therefore, covered SEMS with longer stent patency and fewer migrations are required. This study aimed to assess the clinical performance of a novel, fully covered SEMS for unresectable MDBO.Methods: This was a multicenter single-arm prospective study. The primary outcome was a non-obstruction rate at 6 months. The secondary outcomes were overall survival (OS), recurrent biliary obstruction (RBO), time to RBO (TRBO), technical and clinical success, and adverse events.Results: A total of 73 patients were enrolled in this study. The non-obstruction rate at 6 months was 61%. The median OS and TRBO were 233 and 216 days, respectively. The technical and clinical success rates were 100% and 97%, respectively. Furthermore, the rate of occurrence of RBO and adverse events was 49% and 21%, respectively. The length of bile duct stenosis (<2.2 cm) was the only significant risk factor for stent migration.Conclusions: The non-obstruction rate of a novel fully covered SEMS for MDBO is comparable to that reported earlier but shorter than expected. Short bile duct stenosis is a significant risk factor for stent migration.


  • 446: PREDICTING OUTCOMES USING AN EARLY HOSPITALIZATION PANCREATITIS ACTIVITY SCORING SYSTEM: A LARGE PROSPECTIVE MULTICENTER STUDY

    by Masayasu Horibe, Eisuke Iwasaki, Yoshihisa Tsuji, Mayumi Toshihiko, Masamitsu Sanui, Takaaki Eguchi, Ken Emoto, Taku Oshima, Takuya Yokota, Atsuto Kayashima, et al.

  • Reducing the risk of developing walled‐off necrosis in patients with acute necrotic collection using recombinant human soluble thrombomodulin

    by Takaaki Eguchi, Yoshihisa Tsuji, Akihiko Okada, Dai Inoue, Hironobu Tokumasu, Kosuke Iwane, Yoshitaka Nakai, Toshihiro Kusaka, Yoshito Uenoyama, Koichi Fujita, et al.

    Purpose To investigate possibility of reducing clinical impacts of acute necrotic collection (ANC) on the patients with acute pancreatitis (AP) using recombinant human soluble thrombomodulin (rTM). Methods In this retrospective multicenter study, consecutive 233 AP patients with ANC and acute peripancreatic fluid collection (APFC) from 2012 to 2016 were enrolled. To assess clinical impacts of ANC, severity on admission (JPN score, JPN CT grade, and Modified CT severity index), development of walled-off necrosis (WON), imaging costs for follow-up, and mortality were recorded. Finally, we investigated whether rTM could reduce the clinical impacts, adjusting the severity using propensity analysis with Inverse probability of treatment weighting. Results Patients with ANC developed WON with higher ratio than APFC {58/98 (59.2%) vs. 20/135(14.8%), OR=8.3, p<0.01}. Severity on admission and imaging costs for follow-up in ANC patients were significantly higher than those in APFC (p<0.01). However, regarding mortality, there was no significant different between patients with ANC and APFC (p=0.41). Adjusting severity, it was revealed that rTM administration significantly reduced the risk of ANC developed WON (OR=0.23, p=0.01). Conclusions While ANC had a higher clinical impact than that of APFC, we found that early administration of rTM may reduce the impact.


  • Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute cholangitis (Recover‐AC study)

    by Takeshi Ogura, Takaaki Eguchi, Kazunari Nakahara, Yoshihide Kanno, Shunsuke Omoto, Masahiro Itonaga, Taira Kuroda, Akitoshi Hakoda, Seitaro Ikeoka, Megumi Takagi, et al.

    Background and Aim: Recombinant thrombomodulin (rhTM) is potentially effective in the treatment of disseminated intravascular coagulation (DIC). Several studies related to drugs for the treatment of acute cholangitis have shown negative results in improvement of overall survival (OS) with rhTM. The aim of this multicenter study was to evaluate the clinical effectiveness of rhTM in patients with acute cholangitis and sepsis‐induced DIC who underwent biliary drainage.Methods: A total of 284 consecutive patients, who were complicated with sepsis‐induced DIC due to severe acute cholangitis, were included (rhTM group, n = 173; non‐rhTM, n = 111) in this study. The primary outcome was the DIC resolution rate at 7 days after starting treatment. The 28‐day survival rate was secondarily evaluated.Results: DIC scores in the rhTM group improved significantly compared with the non‐rhTM group on day 7 (P = .020). According to multivariate analysis, etiology of cholangitis (malignant, HR 2.28), rhTM (non‐administration, HR 4.13), and DIC score (≥5, HR 2.46) were significant factors associated with failed DIC resolution on day 7. Propensity score matching created 103 matched pairs. Survival rate at day 28 was significantly higher in rhTM group (94.3%) compared with non‐rhTM group (82.6%; P = .048) after propensity score matching. rhTM (non‐administration, HR 2.870), DIC score (≥5, HR 2.751), and APACHE II score (≥20, HR 9.310) were significant factors associated with decreasing survival rate at day 28.Conclusion: In conclusion, rhTM seemed to improve patient survival, but future studies should only include patients with benign or malignant disease and should be performed according to APACHE II scores.


  • A rare case of pyogenic granuloma of the jejunum causing gastrointestinal bleeding

    by Seitaro Ikeoka, Tetsuya Yoshizaki, Tatsuya Matsuda, Norio Katayama, Masanori Matsumoto, Megumi Takagi, Kenji Momose, Takaaki Eguchi, Toshiyuki Morisawa, Akihiko Okada

    Pyogenic granulomas (PG) are lobular capillary hemangiomas mostly found in the mucous membranes of the skin and oral cavity, and rarely occur in the gastrointestinal tract. Here we describe a case of an 84-year-old patient with alcoholic cirrhosis who presented with persistent melena and progressive anemia. Endoscopy showed esophageal varices and he underwent endoscopic variceal ligation (EVL) with transient resolution of anemia. However, due to worsening anemia, he underwent capsule endoscopy that revealed a bleeding tumor in the small intestine. We performed double-balloon endoscopy and found a 7-mm polyp with a white coat located in the jejunum and resected it at a later date. Histological characteristics led to the diagnosis of PG, and the patient’s melena and anemia subsequently improved.


  • Risk Factors for Adverse Events in Patients with Chronic Constipation Following Lubiprostone Administration

    by Takaaki Eguchi, Tetsuya Yoshizaki, Megumi Takagi, Seitaro Ikeoka, Hiroki Hashimura, Norihiro Okamoto, Masanori Matsumoto, Tatsuya Matsuda, Takahiro Miura, Kenji Momose, et al.

    Introduction: Lubiprostone is an effective treatment of chronic constipation (CC). However, as with other stimulant or osmotic laxatives, adverse events (AEs) can make it difficult to continue treatment. This article investigates AE risk factors associated with lubiprostone. Methods: We retrospectively analyzed all 1,338 Japanese patients with CC treated at our hospital from October 2013 to July 2017. All patients were diagnosed with constipation as defined by the Roma III criteria. Enrolled patients received lubiprostone orally (24 or 48 μg daily), after which we investigated the incidence of AEs. The causative factors for diarrhea and nausea, the most common AEs, were examined by the backward logistic regression model. Results: Two hundred eight (15.5%) experienced at least 1 AE. No serious AEs were associated with the study drug. The AEs reported by >1% of patients overall were diarrhea (6.1%) and nausea (4.2%). We performed a multivariate logistic regression using a backward variable selection method to investigate AE risk factors. Factors associated with higher incidence of diarrhea were patient age of 65 years or more (odds ratio: [95% confidence interval]; p value) (2.09: [1.05–4.16]; 0.035). Factors associated with greater likelihood of nausea included female gender (1.99: [1.10–3.61]; 0.023), and the chief complaint was a patient complaining of abdominal pain and fullness (2.07: [1.01–4.22]; 0.046). Conclusions: Understanding AE risk factors can help avoid unnecessary AEs and promote more effective treatment.


  • Open Access

    Feasibility of the lidocaine injection method during esophageal endoscopic submucosal dissection

    by Tetsuya Yoshizaki, Daisuke Obata, Chise Ueda, Norio Katayama, Yasuhiro Aoki, Norihiro Okamoto, Hiroki Hashimura, Masanori Matsumoto, Megumi Takagi, Seitaro Ikeoka, et al.

    Background and Aim: Esophageal endoscopic submucosal dissection (ESD) is often technically difficult due to intraoperative body movements. The level of sedation can be increased to suppress body movements, but this may not be successful in all cases. Using local analgesics for submucosal injection during ESD may aid in conscious sedation. This study evaluated the feasibility of the lidocaine injection method (LIM) during esophageal ESD. Methods: Twenty-nine patients with superficial esophageal cancer were enrolled in this study at Osaka Saiseikai Nakatsu Hospital, and 1% lidocaine + 0.4% hyaluronate sodium was injected into the submucosa underneath the lesion during esophageal ESD. The main outcome was body movements that disturbed the procedure. Results: Most patients were male (90%), with a median age of 70 years (interquartile range [IQR]: 66-75 years old), and the median lesion size was 17 mm (IQR: 12-21 mm). The median injection volume of lidocaine was 70 mg (IQR: 55-79 mg). All lesions were successfully removed en bloc. In all cases, there were no body movements that disturbed the procedure. Regarding adverse events of sedation, five patients (17%) had hypotension, four patients (14%) had bradycardia, and seven patients (24%) had hypoxemia during ESD. Convulsions or arrhythmia as adverse events associated with lidocaine were not observed. Conclusions: Esophageal ESD with LIM did not cause body movements that disturbed the procedure. LIM may help create a stable conscious sedation method for esophageal ESD.


  • Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study)

    by Akira Kurita, Satoru Yasukawa, Yoh Zen, Kenichi Yoshimura, Takeshi Ogura, Eisuke Ozawa, Yoshinobu Okabe, Masanori Asada, Hiroko Nebiki, Minoru Shigekawa, et al.